Lymphoma

Kite Pharma submitted a supplemental biologics license application to the FDA that seeks expanded approval of axicabtagene ciloleucel.

Patients with diffuse large B-cell lymphoma who achieved a durable response to axicabtagene ciloleucel showed evidence of lower circulating tumor DNA levels before and after treatment, according to results of a prospective study.

September is Blood Cancer Awareness Month.

Evaluation of multiple classifiers, both alone and in combination, supports the decision to focus on cell-free DNA methylation patterns to detect cancer and predict the cancer signal origin, according to a presentation at ESMO Congress 2021.

COVID-19 variants pose a greater threat to certain patients with cancer, particularly those with hematologic malignancies, confirming the need to promote vaccination within this population, according to data presented at ESMO Congress 2021.

The FDA granted accelerated approval to zanubrutinib for treatment of patients with relapsed or refractory marginal zone lymphoma who received at least one anti-CD-20-based regimen.

Renier Brentjens, MD, PhD, has been appointed deputy director and chair of the department of medicine of Roswell Park Comprehensive Cancer Center.

A randomized phase 3 trial that evaluated tisagenlecleucel as second-line treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma failed to meet its primary endpoint of improved EFS, according to the agent’s manufacturer.

Most patients who received one of two investigational natural killer cell therapy regimens for relapsed or refractory B-cell lymphoma achieved complete response, according to topline data released by the agents’ manufacturer.

The FDA cleared an investigational new drug application for KITE-363, a chimeric antigen receptor T-cell therapy designed to treat adults with relapsed or refractory large B-cell lymphoma.